Ferrokin BioSciences is developing a safe and effective iron chelator for the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemias. Iron overload is the inevitable complication of chronic transfusion therapy for a variety of refractory anemias the most common of which are beta thalassemia major and sickle cell anemia.